CN118359585A - 共晶体、其药物组合物以及涉及其的治疗方法 - Google Patents

共晶体、其药物组合物以及涉及其的治疗方法 Download PDF

Info

Publication number
CN118359585A
CN118359585A CN202410230044.7A CN202410230044A CN118359585A CN 118359585 A CN118359585 A CN 118359585A CN 202410230044 A CN202410230044 A CN 202410230044A CN 118359585 A CN118359585 A CN 118359585A
Authority
CN
China
Prior art keywords
compound
crystal
degrees
cancer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410230044.7A
Other languages
English (en)
Chinese (zh)
Inventor
B·S·莱恩
C-H·顾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN118359585A publication Critical patent/CN118359585A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202410230044.7A 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法 Pending CN118359585A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
US62/580,501 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
CN201880079771.0A CN111527076B (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880079771.0A Division CN111527076B (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法

Publications (1)

Publication Number Publication Date
CN118359585A true CN118359585A (zh) 2024-07-19

Family

ID=64572453

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410230044.7A Pending CN118359585A (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法
CN201880079771.0A Active CN111527076B (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880079771.0A Active CN111527076B (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法

Country Status (17)

Country Link
US (3) US11345677B2 (enExample)
EP (1) EP3704101A1 (enExample)
JP (3) JP7335877B2 (enExample)
KR (2) KR20240166601A (enExample)
CN (2) CN118359585A (enExample)
AU (2) AU2018360827B2 (enExample)
BR (1) BR112020008598A2 (enExample)
CA (1) CA3081535A1 (enExample)
EA (1) EA202091112A1 (enExample)
IL (2) IL274123B2 (enExample)
MA (1) MA50526A (enExample)
MX (2) MX2020004513A (enExample)
PH (1) PH12020550462A1 (enExample)
SG (1) SG11202003612VA (enExample)
TW (2) TWI839131B (enExample)
UA (1) UA127380C2 (enExample)
WO (1) WO2019090059A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
TW202227446A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 有機化合物之固態形式
WO2023192565A1 (en) 2022-03-31 2023-10-05 Servier Pharmaceuticals Llc Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
WO2025060940A1 (zh) * 2023-09-18 2025-03-27 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
WO2025168757A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815858C (en) * 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
AU2018360827A1 (en) 2020-05-14
IL274123B2 (en) 2024-01-01
SG11202003612VA (en) 2020-05-28
US20210198234A1 (en) 2021-07-01
TWI839131B (zh) 2024-04-11
KR102731624B1 (ko) 2024-11-19
CN111527076B (zh) 2024-03-12
MX2022014792A (es) 2023-01-16
EP3704101A1 (en) 2020-09-09
JP2021501766A (ja) 2021-01-21
EA202091112A1 (ru) 2020-07-23
WO2019090059A1 (en) 2019-05-09
US20220363661A1 (en) 2022-11-17
BR112020008598A2 (pt) 2021-01-26
AU2018360827B2 (en) 2024-02-22
TW201930285A (zh) 2019-08-01
PH12020550462A1 (en) 2021-03-22
US20240343705A1 (en) 2024-10-17
JP7780576B2 (ja) 2025-12-04
AU2024203186A1 (en) 2024-05-30
TWI796377B (zh) 2023-03-21
JP7499377B2 (ja) 2024-06-13
CA3081535A1 (en) 2019-05-09
JP7335877B2 (ja) 2023-08-30
IL305426B1 (en) 2024-06-01
IL274123B1 (en) 2023-09-01
JP2024113028A (ja) 2024-08-21
IL305426A (en) 2023-10-01
US11851417B2 (en) 2023-12-26
CN111527076A (zh) 2020-08-11
IL274123A (en) 2020-06-30
MA50526A (fr) 2020-09-09
JP2023093666A (ja) 2023-07-04
US11345677B2 (en) 2022-05-31
KR20240166601A (ko) 2024-11-26
IL305426B2 (en) 2024-10-01
KR20200095480A (ko) 2020-08-10
MX2020004513A (es) 2020-09-17
UA127380C2 (uk) 2023-08-02
TW202337885A (zh) 2023-10-01

Similar Documents

Publication Publication Date Title
CN111527076B (zh) 共晶体、其药物组合物以及涉及其的治疗方法
US12303512B2 (en) Therapeutically active compounds and their methods of use
EA048730B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA042081B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
US20250034109A1 (en) Salts, cocrystals, pharmaceutical compositions thereof, and methods of treatment involving the same
US20250041283A1 (en) Cocrystal of an idh1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same
AU2022219973A1 (en) Therapeutically active compounds and their methods of use
EA050372B1 (ru) Терапевтически активные соединения и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination